Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00315367
Status:
COMPLETED
Last Update Posted:
2007-10-16
First Post:
2006-04-14
Brief Title:
A fMRIFunctional Magnetic Resonance Imaging Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
Sponsor:
Neurognostics
Organization:
Neurognostics
Study Overview
Official Title:
A Double-Blind Crossover Trial of Aricept in Memory-Impaired Patients With Multiple Sclerosis A Phase IV Demonstration of Functional MRI fMRI as a Surrogate Marker of Brain Activity Associated With Improvement in Memory Function
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if medication designed to improve memory will help patients with Multiple Sclerosis MS who are experiencing memory problems using fMRI to track brain activity
Detailed Description:
Donepezil HCI Aricept is an FDA-approved drug now used to enhance memory in patients with Alzheimers disease The aim of this project is to examine the effects of Donepezil HCI Aricept on memory induced brain activation patterns in the context of a double-blind crossover trial of patients with multiple sclerosis MS We will perform task activation experiments involving two cognitive domains The proposed work on MS patients should yield new information regarding functional anatomic relationships during cognitive activity and how these relationships change as a function of drug treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None